Space Warlord Organ Trading Simulator

Strange Scaffold · 2021 · $19.99 · Simulation · deal grade D

Measured on 2026-10-02 19:50 UTC, 3 days ago. The whole catalog is re-measured daily; a game that just launched can move fast between passes.

• Estimated net residual revenue: $565 to $848 per month
• Opportunity: $707 per month at x1.00 dormancy
• Estimated lifetime owners: 33.1k
• 93% positive across 876 reviews · 5.7 reviews/month

Why it's flagged

• Developer active, last post 8 months ago
• Studio active elsewhere (8 titles tracked), so this one may welcome a partner
• Last discounted 0 months ago, 10 sales in the last 12 months
• Proven demand elasticity: x1.6 review velocity during past deep sales

Analyst notes (AI-assisted)

Note written 2026-09-13; the live figures above take precedence over any numbers in it.

A darkly comedic tycoon sim where you buy and sell organs harvested from cloned space warlords.

Space Warlord Organ Trading Simulator punches well above its player count, sustaining solid mid-range monthly residuals on the strength of unusual art direction, punchy gameplay loop, and exceptionally high review positivity. The developer remains active and the game has never been discounted, suggesting pricing power and potential upside if the title were reintroduced to audiences via publishing or bundle placement. Best suited for publishers seeking catalog depth in the indie-simulation space or developers interested in IP collaboration. Most realistic play: publishing.

• Risk: Niche appeal and short median playtime mean the addressable audience is capped; player churn is structural, not reversible through patching.
• Risk: One negative review flags random crashes; unknown scope or whether this has been addressed since report date.
• Risk: No discount history and zero promotional runs in 12 months suggest either confidence in positioning or passive catalog management; clarify developer intent before outreach.

This case as Markdown · Estimates carry ±30-50% error per title.